Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Artificial Intelligence

Health Technology

Technology

Genetics

Clinical Trials

Rubedo Life Sciences, Inc.

More Like This

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board

Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study

Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Marco Quarta (right), Rubedo Life Sciences CEO and Co-Founder, notarizes the incorporation of Rubedo's European Headquarters in Milan (Photo: Business Wire)

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience.

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

Rubedo Life Sciences scientists (Photo: Business Wire)

Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591